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Since the introduction of docetaxel, research has focused on various approaches to overcome treatment limitations and improve
outcome. This review discusses the pharmacological attempts at treatment optimisation, which include reducing interindividual
pharmacokinetic and pharmacodynamic variability, optimising schedule, route of administration, reversing drug resistance and the
development of structurally related second-generation taxanes.
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The anticancer drug docetaxel (Taxotere
s) is approved for the
treatment of patients with locally advanced or metastatic breast or
non-small-cell lung cancer and androgen-independent metastatic
prostate cancer. The recommended dose ranges from 60 to
100mgm
 2 given as a 1-h intravenous (i.v.) infusion once every
3 weeks. An important limitation associated with docetaxel use is
the unpredictable interindividual variability in efficacy and
toxicity. Since its clinical introduction, attempts to improve
docetaxel treatment have covered various areas: reducing the
interindividual pharmacokinetic (PK) and pharmacodynamic (PD)
variability, optimising schedule, route of administration and drug
formulation, and reversing drug resistance. This review will
discuss pharmacological strategies aimed to overcome the limita-
tions of docetaxel therapy.
ALTERNATIVE SCHEDULES
When treated at a dose of 100mgm
 2 once every 3 weeks, grade 4
neutropenia and febrile neutropenia occur in 75%, respectively
11%, of patients; a dose of 75mgm
 2 only moderately reduces
this incidence (http://www.taxotere.com). For patients with a
poor performance status (PS), multiple comorbidities, decreased
haematological reserves, a history of extensive pretreatment and
severe toxicity, elderly patients and for patients for whom
treatment is palliative, a less toxic schedule seemed desirable.
Therefore, a schedule involving weekly administration was
developed. Numerous trials have evaluated this schedule; however,
due to considerably different study populations and small sample
sizes, comparisons of weekly vs 3-weekly efficacy were difficult.
Recent randomised trials although demonstrate, for the approved
indications, that the efficacy of weekly docetaxel is comparable to
3-weekly treatment (Engels and Verweij, 2005), the toxicity profiles
are, however, distinctly different. With weekly docetaxel, acute
toxicities, in particular myelosuppression, are mild and never dose
limiting. In contrast, cumulative side effects are much more
prominent. The most common and dose-limiting toxicity is
fatigue/asthenia. These side effects can only be managed by
reducing the dose or by shortening the schedule to 2–3
consecutive weekly infusions, followed by a 1-week rest interval.
Other cumulative toxicities include alopecia, excessive tearing and
nail disorders. Although the latter two side effects are usually mild,
they are persistent, can lead to treatment discontinuation and have
a substantial negative impact on a patient’s quality of life. Given
the similar efficacy observed for the two schedules and the remarks
on toxicity, it is reasonable to conclude that, at this point, 3-weekly
docetaxel is still the standard and most convenient schedule.
Treatment with weekly docetaxel should only be considered as an
alternative for specific patient populations.
PK OPTIMISATION
The PK of total docetaxel are linear and independent of schedule.
Nonetheless, there is a large interpatient variability in exposure
(AUC) and drug clearance (Bruno et al, 1998; Hirth et al, 2000;
Rudek et al, 2004; Baker et al, 2005; ten Tije et al, 2005). In a large
population, PK/PD analysis variability in efficacy and toxicity was
associated with variability in PK (Bruno et al, 1998); a 50%
decrease in docetaxel clearance increased the odds of developing
grade 4 neutropenia and febrile neutropenia 4.3-fold, respectively
3.0-fold. Subsequent studies have therefore focused on identifying
factors, which most affect PK variability. Ultimately, reducing
interpatient exposure variability should improve the risk–benefit
ratio of docetaxel therapy.
Initially, the main predictors of total docetaxel clearance
(variability) were body surface area (BSA), a1-acid glycoprotein
(AAG), hepatic function (elevated alkaline phosphatase (ALKPH)
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www.bjcancer.comand transaminases levels) and age (Bruno et al, 1996). More
recently (hepatic), cytochrome P450 isozyme 3A4 (CYP3A4)
activity was also included (Hirth et al, 2000). The relevance of all
these predictors to docetaxel dose optimisation has been further
(re-) evaluated.
Normalisation of clearance for BSA reduces interindividual
variability marginally (o2%), thus questioning the clinical rele-
vance of BSA-based dosing (Rudek et al, 2004). Clearance was,
however, significantly higher by 33% (P¼0.0029) for patients with
BSA values 42.00m
2 compared to values o1.71m
2. Flat dosing,
possibly differentiating for extremes of BSA (42.00m
2), may be
easier and just as precise and should be investigated prospectively.
In general, the unbound (i.e. free) fraction of any drug is
pharmacologically active. In serum, docetaxel is extensively bound
to albumin, lipoproteins and AAG; indeed, the latter is the main
determinant of docetaxel serum binding variability. Furthermore,
AAG levels in cancer patients vary at least four-fold (Bruno et al,
1998; Loos et al, 2003; Baker et al, 2005). High AAG levels have
been associated with a decrease in the unbound fraction of
docetaxel in vitro, and with reduced total docetaxel clearance
(Bruno et al, 1996; Loos et al, 2003) and lower response rate in
man (Bruno et al, 1998). Yet, dosing recommendations based on
individual AAG levels are not available. The formulation vehicle
polysorbate 80, although rapidly degraded by serum esterases, also
influences docetaxel protein binding, increasing the unbound drug
fraction by on average 16–24% at peak polysorbate 80 concentra-
tions (Loos et al, 2003; Baker et al, 2005). Furthermore, higher
polysorbate 80 exposure resulted in lower unbound docetaxel
clearance. Most importantly, haematological toxicity is highly
correlated with systemic exposure to unbound docetaxel (Baker
et al, 2005). Thus, measuring unbound docetaxel concentrations
should be considered in future PK/PD studies.
Mild hepatic impairment (total bilirubin o1.5 ULN, trans-
aminases X1.5 to p3.5 ULN concurrent with ALKPH X2.5 to
p5 ULN) decreases total docetaxel clearance by 27% (Bruno
et al, 1998), and moderate (total bilirubin X1.5 to o3.0 ULN
with any transaminase and ALKPH elevations) to severe impair-
ment (total bilirubin X3.0 ULN with any transaminase and
ALKPH elevations) does so by 50%. This should obviously have
consequences, yet one is only warned that docetaxel should
generally not be given to patients with total bilirubin 4ULN,
or with transaminases 41.5 ULN concomitant with ALKPH
42.5 ULN (www.taxotere.com). Dose adjustments therefore are
left to the discretion of the physician, while they seem required.
Elderly age (X65 years) does not alter total docetaxel PK (ten
Tije et al, 2005). Interestingly, the elderly patients’ serum AAG
levels were significantly (Pp0.04), albeit only slightly lower.
Decreased AAG levels contribute to higher exposure to unbound
docetaxel resulting in more myelosuppression (Baker et al, 2005).
Jointly with the increased susceptibility for myelosuppression due
to a functional decline in haematological reserves at ageing, this
could be a concern. Yet, toxicity did not occur more frequently in
the elderly. Thus, age-related dose recommendations should
predominantly be based on individual PS and comorbidity.
Docetaxel is primarily metabolised by (hepatic and intestinal)
CYP3A, in particular by isoforms CYP3A4 and CYP3A5, the latter
of which has a 10-fold lower affinity for docetaxel. Docetaxel
metabolites are substantially less active than the parent drug;
hence, CYP3A-mediated metabolism is the major route of
inactivation. CYP3A activity in adults, and in patients treated
with docetaxel, varies largely between individuals. This is believed
to depend on environmental (CYP3A modulation), physiological
(hepatic impairment) and genetic (CYP3A polymorphism) factors.
Pretreatment CYP3A phenotyping has been suggested as a tool to
individualise docetaxel dosing (Rivory et al, 2000; Goh et al, 2002;
Puisset et al, 2004; Yamamoto et al, 2005). At present, the
midazolam hydroxylation test and the erythromycin breath test
(ERMBT) are the most widely applied phenotyping strategies,
albeit that both have their limitations. The ERMBT did not
consistently correlate with results from other CYP3A phenotypic
probes (Chiou et al, 2001) and may have limited value for CYP3A
phenotyping of docetaxel patients as erythromycin is preferentially
metabolised by CYP3A4, whereas docetaxel is metabolised by
CYP3A4 and CYP3A5. Yet, when compared to other variables
(ALKPH, alanine aminotransferase and AAG), the ERMBT was the
best single predictor of docetaxel clearance (Hirth et al, 2000) and
probe specificity issues are relevant only in individuals expressing
significant CYP3A5 levels, which is rarely the case in Caucasians.
In contrast, African-Americans have much higher CYP3A5
expression and in these patients midazolam, metabolised by both
CYP3A4 and CYP3A5, may be more suitable. Clinical trials
correlating phenotyping results to docetaxel PK demonstrate that
midazolam, erythromycin and dexamethasone are predictors of
docetaxel clearance (Hirth et al, 2000; Goh et al, 2002; Puisset et al,
2004). As dexamethasone is routinely used as premedication, it
may be more attractive as a probe drug than midazolam or
erythromycin. Recently, individualised dosing based on the 24-h
urinary metabolite of exogenous cortisol as phenotypic CYP3A
probe was evaluated (Yamamoto et al, 2005). Individualised
phenotypic dosing significantly reduced the interindividual PK
variability compared to BSA-based dosing. Further larger studies,
preferably comparing phenotyping strategies, are required to
assess which probe is the best predictor of CYP3A activity.
Nonetheless, phenotyping techniques have practical disadvantages
(i.e. 24-h urine collection, radioisotope administration) that, may
limit their applicability in common oncology practice.
The involvement of CYP3A in docetaxel elimination renders the
drug potentially subject to a host of enzyme-mediated PK drug
interactions with conventional drugs, complementary and alter-
native medicine and food constituents that interfere with CYP3A
function or expression. Docetaxel has a narrow therapeutic
window. Therefore, the risk of a PK interaction resulting in under-
or overexposure, thereby modifying treatment outcome, is high.
For several coadministered cytotoxic agents, PK interactions with
docetaxel are known and have led to dose or schedule
recommendations. Interestingly, for the potent CYP3A inhibitor
ketoconazole interaction data are inconsistent. Both trials ob-
served large interindividual variability in the reduction of
docetaxel clearance (Van Veldhuizen et al, 2003; Engels et al,
2004). Yet, in one this was highly significant (Engels et al, 2004)
whereas in the other, although docetaxel clearance decreased 2–4-
fold in 25% of the patients, thus increasing the risk for severe
neutropenia, it was not (Van Veldhuizen et al, 2003). Efforts to
reduce the interindividual PK variability through inhibition of
CYP3A by ketoconazole have not been successful. No clinically
relevant PK interaction has been observed between dexametha-
sone, a possible CYP3A inducer, and docetaxel (Hirth et al, 2000;
Goh et al, 2002). Thus, there is no reason to abandon routine
dexamethasone premedication. Clearly, the degree to which a PK
interaction is clinically relevant, and requires an intervention
depends upon the CYP3A-inducing or -inhibiting properties of the
coadministered agent. Since specific dose adjustment recommen-
dations are not available, concomitant administration of potent
CYP3A-modulating comedication should generally be avoided.
Docetaxel is also a substrate for the ATP-binding cassette
transmembrane transporter protein ABCB1 (P-glycoprotein
(P-gp); MDR-1). ABCB1 is expressed in tumours and in normal
tissues including the blood–brain–barrier (BBB), biliary tract and
intestinal epithelium. Although ABCB1 plays a (major) role in the
intestinal absorption and biliary excretion of orally administered
substrates, its influence on the plasma PK of i.v. administered
drugs, including docetaxel, is minimal to absent (van Zuylen et al,
2000). ABCB1 inhibition does, however, significantly influence the
faecal disposition of docetaxel, reducing the amount of excreted
unchanged drug (approximately 18-fold) without affecting plasma
PK (van Zuylen et al, 2000), indicating that the effects of ABCB1
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only plasma.
Monitoring plasma levels and PK-guided dose adjustments is
referred to as therapeutic drug monitoring (TDM). At present, the
use of TDM in oncology is limited. A prerequisite for TDM is that
intraindividual PK variability is less than interindividual PK
variability, which is the case for docetaxel. For reasons of patient
convenience and practicality, validated limited sampling strategies
(LDS), requiring only two to four samples to characterise an
individual PK profile (Bruno et al, 1996, 1998), should be used.
LDS used in combination with a population PK model and
Bayesian analysis allows individual PK parameters to be estimated
with adequate precision while sampling and dosing times remain
flexible. TDM could become an interesting strategy to docetaxel
dose individualisation provided a target concentration or exposure
profile can be defined. It should be noted, however, that obtaining
two to four samples from outpatients requires adequate planning
and a good collaboration between pharmacy, outpatient clinic and
the prescribing oncologist to assure that sampling can be
completed within the service hours of an oncology day unit.
REVERSAL OF DRUG RESISTANCE
The most extensively studied mechanism of acquired or intrinsic
resistance to taxanes is the overexpression of ABCB1. Numerous
(pre)clinical investigations have evaluated coadministration of
ABCB1 (P-gp) modulators (e.g. verapamil, cyclosporin A (CSA),
valspodar), aiming to restore or enhance sensitivity to chemo-
therapy. However, the results were largely disappointing. To over-
come the limitations of these first- and second-generation
modulators (unacceptable toxicity and unpredictable PK interac-
tions), highly specific and potent third-generation ABCB1 modulators,
lacking interference with the plasma PK of cytotoxics, were developed.
In phase I trials, oral and i.v. R101933 (laniquidar) administered
in combination with docetaxel inhibited ABCB1 both in an ex vivo
assay and in vivo (indicated by intestinal P-gp inhibition), and
docetaxel plasma PK was not altered (van Zuylen et al, 2000, 2002).
However, phase II studies were negative. Similar disappointing
efficacy results were obtained in clinical trials of XR9576
(tariquidar) and docetaxel, and at present, there are no plans for
further clinical development (www.qltinc.com). A phase I trial of
docetaxel in combination with the orally administered agent
LY335979 (zosuquidar) showed no PK interaction (Fracasso et al,
2004). The limited cerebrospinal fluid penetration of docetaxel
is also assumed to be due to ABCB1-mediated drug efflux and
restricts treatment of brain tumours with docetaxel. Preclinical
investigations with GF120918 (elacridar) suggested increased
docetaxel brain concentrations without any effect on plasma PK
(Kemper et al, 2004), but a phase I trial reported increased systemic
exposure to docetaxel and reduced clearance (Lokiec et al, 2003).
This interaction will likely limit further clinical development.
Docetaxel is also a substrate of CYP1B1, a cytochrome isozyme
not detected in human liver but (over)expressed in various
tumours. In vitro docetaxel cytotoxicity in cells transfected with
human CYP1B1 was decreased (McFadyen et al, 2001), but
CYP1B1-mediated docetaxel metabolism was not affected
(Bournique and Lemarie, 2002). Meanwhile, the ability of CYP1B1
inhibitors to increase the cytotoxic effect of docetaxel has recently
been demonstrated in vitro. Clinical studies have not yet been
performed and the functional role of intratumoral CYP1B1
(-mediated resistance) on docetaxel cytotoxicity remains to be
elucidated.
Clearly, the ultimate (multi)drug resistance reversal agent is not
(yet) available. Moreover, one should realise that modulating one
resistance mechanism will not yield important antitumour benefit,
given the large number of resistance mechanisms in human
tumour tissue.
ALTERNATIVE ROUTES OF ADMINISTRATION –
ORAL ADMINISTRATION
In vitro increasing the duration of taxane exposure above a
threshold level is more important than achieving high peak
concentrations. Clinically, the duration of exposure to plasma
levels greater than 0.080mg/ml indeed predicted response (Bruno
et al, 1998). Oral docetaxel treatment would be a patient-
convenient way to achieve long-term drug exposure. However,
development of a suitable oral formulation has been impeded by
low (o10%) and highly variable oral bioavailability, due to the
discussed extensive CYP3A-mediated first-pass metabolism and, to
a lesser degree, to affinity for outward-directed transport by
ABCB1 in the gastrointestinal tract. Modulating these elimination
routes has therefore been a focus of research.
In wild-type mice, exposure to orally administered docetaxel
was six-fold lower compared to Abcb1a/1b knockout mice
(Bardelmeijer et al, 2002). More importantly, the relative bioavail-
ability increased from 4 to 183% by coadministration of the potent
CYP3A (and poor ABCB1) inhibitor ritonavir, increasing systemic
exposure 50-fold. Subsequently, a small PK study, in which
patients were given oral docetaxel (75mgm
 2) with or without the
ABCB1 and CYP3A inhibitor CsA, confirmed the observation
(Malingre et al, 2001). In the presence of CsA, systemic exposure
increased approximately seven-fold (from 0.3770.33 to 2.717
1.81mgh
 1l
 1). When given 100mgm
 2 docetaxel i.v. (without
CsA), the resulting systemic exposure was 4.2772.26mgh
 1l
 1.
Adjusted for the difference in dose, exposure following oral
administration with concomitant CsA does not greatly differ from
exposure after i.v. administration without CsA. The investigators
performed a phase II trial with weekly oral docetaxel (100mg)
in combination with CsA (Kruijtzer et al, 2001). Interpatient
PK variability, haematological toxicity and antitumour activity
seem to be in the same range as for intravenous docetaxel. Oral
docetaxel (100mg) was also combined with OC144-093, a potent
and selective oral ABCB1 inhibitor, and compared to 100mg i.v.
docetaxel (Kuppens et al, 2005). The relative oral bioavailability of
docetaxel was 2678%, lower than previously observed after CsA
coadministration and systemic exposure after i.v. docetaxel was
administered three-fold higher compared to the oral application,
despite the ABCB1 modulation. This indicating that CYP3A-
mediated (first-pass) metabolism is the crucial process involved in
the poor oral bioavailability of docetaxel.
Notwithstanding the fact that the oral bioavailability of doce-
taxel can be increased through pharmacologic modulation, the
development of second-generation oral taxanes is likely to prevail.
SECOND-GENERATION DOCETAXEL-BASED TAXANES
Lately, structure-activity relationship studies have focused on
identifying novel structurally related docetaxel analogues with
increased cytotoxicity in resistant tumours, increased penetration
across the BBB, decreased toxicity, oral bioavailability and higher
water solubility, the latter facilitating drug formulation. Chemical
modification of the core structure of docetaxel has resulted in
docetaxel-based second-generation taxanes, which are in different
phases of clinical development (Table 1).
Docetaxel is synthesised from 10-deacetylbaccatin III, a
noncytotoxic precursor derived from the European yew tree.
Research initially focused on modifications of this compound and
yielded XRP9881 (RPR109881A) and XRP6258 (RPR116258A or
TXD258). Both agents have comparable mechanism of action to
docetaxel, and in tumour models sensitive to docetaxel, cytotoxic
activity was similar to docetaxel (http://www.AventisOncology.
com). Importantly, in vitro these agents are characterised by
potent growth inhibitory activity in moderately and highly
docetaxel-resistant cell lines, most probably based upon a
substantially lower affinity for ABCB1. Furthermore, glioblastoma
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penetration of the BBB. Phase I trials and early phase II studies
with XRP9881 in metastatic breast cancer patients suggest
adequate activity (Kurata et al, 2000). A differentiating feature of
XRP6258 is its antitumour activity following oral administration,
yet initial development is as intravenous administration. Both
agents demonstrate marked interpatient variability in drug
clearance, similar to docetaxel. Short-lasting and manageable
neutropenia, fatigue and diarrhoea are the dose-limiting toxicities.
Several cytotoxic analogues derived from 14-b-hydroxy-10-
deacetylbaccatin III, a natural compound closely related to the
core structure of docetaxel, have been evaluated. The most
interesting is ortataxel (IDN5109, BAY 59-8862). Ortataxel has
adequate oral bioavailability and can modulate the function of
various ABC transporter proteins, including ABCB1, MRP and
BCRP (Minderman et al, 2004). The drug is not active in renal
cancer patients, and phase II studies in taxane-resistant metastatic
breast cancer and NCSLC patients are ongoing. MAC-321 or
TL00139 exhibits a similar mechanism of cytotoxic activity as
docetaxel (Sampath et al, 2003), is highly effective both orally and
intravenously administered and currently under investigation
involving both administration routes. DJ-927 is a novel semisyn-
thetic taxane with high water solubility, lack of neurotoxicity, good
oral bioavailability and superior antitumour activity compared to
docetaxel in in vitro and in vivo models (Shionoya et al, 2003).
Preliminary results of a phase I trial of orally administered DJ-927
suggest that the agent may have favourable toxicological and
pharmacological properties.
CONCLUSION
Continued research has offered us new and complementary
insights on various aspects of docetaxel treatment, and yet, dose
and schedule are still based on initial recommendations. Although
this may sound disappointing, important steps forward have been
made (Table 2) and research is ongoing. Besides the discussed
areas of treatment optimisation, future investigations will focus
on further development of preclinically promising alternative
formulations, on pharmacogenomic-based treatment optimisation
and on pharmacogenetic-based dose individualisation strategies.
However, given the large, ethnically diverse population studies
required, introduction of the latter two strategies is not expected in
the foreseeable future. On shorter term, it is likely that TDM will be
explored as it provides a potential tool for rapidly achievable
treatment optimisation.
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